37 results match your criteria: "USA. [2] Johns Hopkins University[Affiliation]"
The impact of dynamic balance measures on walking performance in multiple sclerosis.
Neurorehabil Neural Repair
January 2015
Kennedy Krieger Institute, Baltimore, MD, USA Johns Hopkins University, Baltimore, MD, USA
Background: Static posture imbalance and gait dysfunction are common in individuals with multiple sclerosis (MS). Although the impact of strength and static balance on walking has been examined, the impact of dynamic standing balance on walking in MS remains unclear.
Objective: To determine the impact of dynamic balance, static balance, sensation, and strength measures on walking in individuals with MS.
Response to letter to the editor.
Pain
May 2014
Departments of Anesthesiology and Neurology and Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA University of Rochester, Rochester, NY, USA Stanford University, Palo Alto, CA, USA Johns Hopkins University, Baltimore, MD, USA Oregon Health and Science University, Portland, OR, USA Northwestern University, Chicago, IL, USA University of Wisconsin, Madison, WI, USA University of Kiel, Kiel, Germany Schmerzfachpraxis, Krefeld, Germany University of Washington, Seattle, WA, USA Universität Heidelberg, Mannheim, Germany Pain Matters, Liverpool, UK.
Interventional management of neuropathic pain: NeuPSIG recommendations.
Pain
November 2013
Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA University of Rochester, Rochester, NY, USA Stanford University, Palo Alto, CA, USA Johns Hopkins University, Baltimore, MD, USA Oregon Health and Science University, Portland, OR, USA Northwestern University, Chicago, IL, USA University of Wisconsin, Madison, WI, USA University of Kiel, Kiel, Germany Schmerzfachpraxis, Krefeld, Germany University of Washington, Seattle, WA, USA Universität Heidelberg, Mannheim, Germany Pain Matters, Liverpool, UK.
Neuropathic pain (NP) is often refractory to pharmacologic and noninterventional treatment. On behalf of the International Association for the Study of Pain Neuropathic Pain Special Interest Group, the authors evaluated systematic reviews, clinical trials, and existing guidelines for the interventional management of NP. Evidence is summarized and presented for neural blockade, spinal cord stimulation (SCS), intrathecal medication, and neurosurgical interventions in patients with the following peripheral and central NP conditions: herpes zoster and postherpetic neuralgia (PHN); painful diabetic and other peripheral neuropathies; spinal cord injury NP; central poststroke pain; radiculopathy and failed back surgery syndrome (FBSS); complex regional pain syndrome (CRPS); and trigeminal neuralgia and neuropathy.
View Article and Find Full Text PDFJitter Reduces Response-Time Variability in ADHD: An Ex-Gaussian Analysis.
J Atten Disord
September 2015
Kennedy Krieger Institute, Baltimore, MD, USA Johns Hopkins University, Baltimore, MD, USA
Objective: "Jitter" involves randomization of intervals between stimulus events. Compared with controls, individuals with ADHD demonstrate greater intrasubject variability (ISV) performing tasks with fixed interstimulus intervals (ISIs). Because Gaussian curves mask the effect of extremely slow or fast response times (RTs), ex-Gaussian approaches have been applied to study ISV.
View Article and Find Full Text PDFResearch design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations.
Pain
October 2012
University of Washington, Seattle, Washington, USA University of Rochester, Rochester, New York, USA Johns Hopkins University, Baltimore, Maryland, USA Analgesic Solutions and Tufts University, Boston, Massachusetts, USA Covance, Conshohocken, Pennsylvania, USA Harvard Medical School, Boston, Massachusetts, USA Columbia University, New York, USA Denver Health Authority and Rocky Mountain Poison and Drug Center, Denver, Colorado, USA University of North Carolina, Chapel Hill, North Carolina, USA National Institute on Drug Abuse, Bethesda, Maryland, USA United States Food and Drug Administration, Silver Spring, Maryland, USA CNS Drug Consulting, McLean, Virginia, USA University of Chicago, Chicago, Illinois, USA Endo Pharmaceuticals, Chadds Ford, Pennsylvania, USA American Chronic Pain Association, Rocklin, California, USA AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA Brigham and Women's Hospital, Boston, Massachusetts, USA AcelRx Pharmaceuticals, Redwood City, California, USA University of Texas Health Science Center San Antonio, San Antonio, Texas, USA Johnson & Johnson Pharmaceutical Research & Development, Titusville, New Jersey, USA Pfizer, New Brunswick, New Jersey, USA Clinical Research and Pain Clinic, Salt Lake City, Utah, USA NAMA Recovery, Cedar Park, Texas, USA.
Opioids are essential to the management of pain in many patients, but they also are associated with potential risks for abuse, overdose, and diversion. A number of efforts have been devoted to the development of abuse-deterrent formulations of opioids to reduce these risks. This article summarizes a consensus meeting that was organized to propose recommendations for the types of clinical studies that can be used to assess the abuse deterrence of different opioid formulations.
View Article and Find Full Text PDFConsiderations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations.
Pain
June 2012
Departments of Anesthesiology and Neurology and Center for Human Experimental Therapeutics, University of Rochester, Rochester, NY 14642, USA University of Washington, Seattle, WA, USA University of Rochester, Rochester, NY, USA United States Food and Drug Administration, Silver Spring, MD, USA University of Pennsylvania, Philadelphia, PA, USA Queen's University, Kingston, ON, Canada Analgesic Solutions, Natick, MA, USA Tufts University, Boston, MA, USA Johns Hopkins University, Baltimore, MD, USA California Pacific Medical Center Research Institute, San Francisco, CA, USA University of Wisconsin, Madison, WI, USA University of Kiel, Kiel, Germany University of Queensland, Brisbane, Australia Bristol-Myers Squibb, Wallingford, CT, USA American Chronic Pain Association, Rocklin, CA, USA DePuy Spine, Raynham, MA, USA Pfizer, New London, CT, USA Eisai Limited, Mosquito Way, Hatfield, UK Department of Veterans Affairs, West Haven, CT, USA Yale University, New Haven, CT, USA Nuvo Research, West Chester, PA, USA Endo Pharmaceuticals Inc., Chadds Ford, PA, USA Durect Corporation, Cupertino, CA, USA AstraZeneca, Wilmington, DE, USA Purdue Pharma, Stamford, CT, USA National Institutes of Health, Bethesda, MD, USA Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA Imperial College, London, UK Faculdade de Medicina de Lisboa, Lisbon, Portugal Eli Lilly & Co., Indianapolis, IN, USA King Pharmaceuticals (currently Pfizer), Cary, NC, USA Oregon Health and Science University, Portland, OR, USA Grünenthal GmbH, Aachen, Germany NeurogesX, Inc., San Carlos, CA, USA Harvard Medical School, Boston, MA, USA University of Ottawa, Ottawa, ON, Canada Smith & Nephew, Durham, NC, USA German Diabetes Center, Heinrich Heine University, Düsseldorf, Germany.
A number of pharmacologic treatments examined in recent randomized clinical trials (RCTs) have failed to show statistically significant superiority to placebo in conditions in which their efficacy had previously been demonstrated. Assuming the validity of previous evidence of efficacy and the comparability of the patients and outcome measures in these studies, such results may be a consequence of limitations in the ability of these RCTs to demonstrate the benefits of efficacious analgesic treatments vs placebo ("assay sensitivity"). Efforts to improve the assay sensitivity of analgesic trials could reduce the rate of falsely negative trials of efficacious medications and improve the efficiency of analgesic drug development.
View Article and Find Full Text PDFAssociation of catastrophizing with interleukin-6 responses to acute pain.
Pain
November 2008
Department of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Pain Management Center, Brigham & Women's Hospital, 850 Boylston Street, Chestnut Hill, MA 02467, USA Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 North Wolfe St, Baltimore, MD 21287, USA Department of Psychology, University of Maryland at Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250, USA Johns Hopkins University School of Nursing, 525 North Wolfe St, Baltimore, MD 21205, USA.
Catastrophizing exerts its deleterious effects on pain via multiple pathways, and some researchers have reported that high levels of catastrophizing are associated with enhanced physiological reactivity to painful stimulation. In this project, 42 generally healthy adults underwent a series of psychophysical pain testing procedures assessing responses to noxious mechanical, heat, and cold stimuli. Pain catastrophizing cognitions were assessed prior to and then immediately after the various pain induction procedures.
View Article and Find Full Text PDFSleep onset insomnia symptoms during hospitalization for major burn injury predict chronic pain.
Pain
September 2008
Johns Hopkins University School of Medicine, Department of Psychiatry, USA Johns Hopkins University School of Nursing, USA University of Texas - Southwestern Medical Center, USA University of Washington, Harborview Burn Center, USA University of Texas, Medical Branch, USA University of Colorado, Health Sciences Center, USA.
Both cross-sectional studies of chronic pain and sleep deprivation experiments suggest a bi-directional relationship between sleep and pain. Few longitudinal studies, however, have assessed whether acute insomnia following traumatic injury predicts the development of persistent pain. We sought to evaluate (1) whether in-hospital insomnia independently predicts long-term pain after burn injury and (2) whether in-hospital pain predicts future insomnia symptoms.
View Article and Find Full Text PDFWafer-level assembly of carbon nanotube networks using dielectrophoresis.
Nanotechnology
February 2008
Department of Physics, Georgetown University, Washington, DC 20057, USA. Johns Hopkins University Applied Physics Laboratory, Laurel, MD 20723, USA.
We use dielectrophoresis (DEP) to controllably and simultaneously assemble multiple carbon nanotube (CNT) networks at the wafer level. By an appropriate choice of electrode dimensions and geometry, an electric field is generated that captures CNTs from a sizable volume of suspension, resulting in good CNT network uniformity and alignment. During the DEP process, the electrical characteristics of the CNT network are measured and correlated with the network morphology.
View Article and Find Full Text PDFDeveloping patient-reported outcome measures for pain clinical trials: IMMPACT recommendations.
Pain
December 2006
University of Washington, Seattle, WA 98195, USA University of Rochester School of Medicine and Dentistry, Rochester, NY, USA United States Food and Drug Administration, Rockville, MD, USA Northwestern University, Chicago, IL, USA Johnson and Johnson, Raritan, NY, USA AstraZeneca, Wilmington, DE, USA University of California San Diego, La Jolla, CA, USA Merck and Company, Blue Bell, PA, USA University of Texas, M.D. Anderson Cancer Center, USA American Chronic Pain Association, Rocklin, CA, USA Allergan, Inc, Irvine, CA, USA National Institute of Dental and Craniofacial Research, Bethesda, MD, USA University of Pennsylvania, Philadelphia, PA, USA Johns Hopkins University, Baltimore, MD, USA University Health Network and University of Toronto, Toronto, Canada Novartis Pharmaceuticals, East Hanover, NJ, USA VA Connecticut Healthcare System, West Haven, CT, USA Yale University, New Haven, CT, USA Celgene Corporation, Warren, NJ, USA Pfizer Global Research and Development, Ann Arbor, MI, USA Dalhousie University, Halifax, Nova Scotia, Canada London Regional Cancer Centre, London, Ont., Canada University of Liverpool, Liverpool, UK GlaxoSmithKline, Research Triangle Park, NC, USA Johnson & Johnson, Raritan, NJ, USA Alpharma, Elizabeth, NJ, USA Harvard Medical School, Boston, MA, USA Alpharma, Piscataway, NY, USA University of Munich, Munich, Germany US Department of Veterans Affairs, Washington, DC, USA NeurogesX, Inc, San Carlos, CA, USA Eli Lilly and Co., Indianapolis, IN, USA Endo Pharmaceuticals Inc., Chadds Ford, PA, USA St. Thomas Hospital, London, UK Saint Louis University, St. Louis, MO, USA.
Identification of subgroups of persons with chronic pain based on profiles on the pain stages of change questionnaire.
Pain
August 2005
VA Connecticut Healthcare System and Yale University, Campbell Avenue, West Haven, CT 06516, USA University of Connecticut Health Center, Farmington, CT 06030, USA Pfizer, Inc., Groton, CT 06340, USA Johns Hopkins University, Baltimore, MD 21287, USA Dartmouth Medical School, Lyme, NH 03768, USA.
This study sought to identify reliable subgroups of patients with chronic pain based on profiles of subscale scores on the Pain Stages of Change Questionnaire (PSOCQ), a reliable and valid measure of individuals' readiness to adopt a self-management approach to chronic pain. The PSOCQ was administered to 633 people seeking treatment for chronic pain. Participants were predominantly White, averaged 48 years of age, about half were men, and about half reported back pain as the primary complaint.
View Article and Find Full Text PDFGrand mal seizures associated with high-dose intravenous morphine infusions: incidence and possible etiology.
Pain
November 1992
The Johns Hopkins Hospital Pharmacy, Baltimore, MD 21205 USA Department of Oncology, Johns Hopkins University, Baltimore, MD 21205 USA Johns Hopkins University School of Nursing, Baltimore, MD 21205 USA Johns Hopkins Oncology Center, Baltimore, MD 21205 USA.
A retrospective review of pharmacy records during a 7-year period at the Johns Hopkins Oncology Center revealed that 6 patients received greater than 4 g of morphine sulfate per day by continuous infusion (CI). Three patients received high-dose infusions for more than 24 h. Two of these 3 patients developed grand mal seizures, while the third was receiving a neuromuscular blocking agent making detection of seizures difficult.
View Article and Find Full Text PDF